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ABSTRACT 
Designing therapeutic devices capable of manipulating glioblastoma initiating cells (GICs) is 
critical to stop tumor recurrence and its associated mortality. Previous studies have indicated 
that bone morphogenetic protein-7 (BMP-7) acts as an endogenous suppressor of GICs, and 
thus, it could become a treatment for this cancer. In this work, we engineer an implantable 
microsphere system optimized for the controlled release of BMP-7 as a bioinspired therapeutic 
device against GICs. This microsphere delivery system is based on the formation of a heparin-
BMP-7 nanocomplex, first coated with Tetronic® and further entrapped in a biodegradable 
polyester matrix. The obtained microspheres can efficiently encapsulate BMP-7, and release it 
in a controlled manner with minimum burst effect for over two months while maintaining protein 
bioactivity. Released BMP-7 showed a remarkable capacity to stop tumor formation in a GICs 
cell culture model, an effect that could be mediated by forced reprogramming of tumorigenic 
cells towards a non-tumorigenic astroglial lineage. 
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1. INTRODUCTION 
High-grade malignant astrocytic gliomas are the most common and aggressive primary central 
nervous system tumors, accounting for 52% of all primary brain cancer cases [1]. Glioblastoma 
multiforme (GBM) is the most common glioma in adults and the typical survival of the patients is 
around one year [2, 3], a prognosis that has stalled in the last decades. It is now becoming clear 
that this intrinsic resistance of GBM to current treatments is caused by a cell subpopulation with 
high resistance to radiation and chemotherapy: glioblastoma initiating cells (GICs) [4-7]. GICs are 
also responsible for tumor reinitiation and sustained growth and this is why they are 
conceptualized as cancer´s locomotive engine [8]. Besides, the location of glioblastomas in the 
brain greatly restricts chemotherapeutic options. For illustration, it is considered that over 98% of 
small molecular weight, and essentially 100% of high molecular weight drugs are not transported 
across the blood-brain-barrier [9, 10].   
Recently, Chirasani et al. disclosed a new physiological role for endogenous neural stem cells. 
This work showed that these stem cells secrete bone morphogenetic protein-7 (BMP-7), and that 
this growth factor acts as a paracrine suppressor of GICs. Animal experiments also showed that 
these cells will migrate to the borders of neoplastic foci to suppress GBM formation, an antitumoral 
protective mechanism that could be expected to diminish with age as the neural stem cell pool is 
exhausted [11]. Indeed, this and other studies have shown that BMPs can arrest cell cycle in 
glioblastoma cells [12], and suppress the tumorigenic capacity of GICs by inducing their 
differentiation to phenotypes with lower levels of stem cell markers [11, 13, 14]. There is now a 
body of evidence supporting a role of BMP-7 as a reprogramming factor of GICs, a process that 
should remove the tumors capacity for recurrence.  
We propose the use of BMP-7-loaded biodegradable implantable microspheres as bioinspired 
therapeutic strategy against GICs. The clinical concept would be to implant these controlled 
release devices upon surgical resection of the primary tumor, to prevent GBM reinitiation. This 
approach intends to overcome two critical constraints for successful delivery of BMP-7 to the brain: 
(i) its inability to cross the blood-brain-barrier, and (ii) its short physiological half-life (few minutes 
[15]). Several intracranial implantable devices have already been described for the treatment of 
GBM with hydrophobic anticancer drugs [8, 16], and one of them is already marketed (Gliadel® 
wafer). The delivery system proposed herein is nevertheless particularly designed for the 
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encapsulation of a labile hydrophilic morphogen and for providing sustained release properties 
over several weeks while preserving the bioactive conformation of the protein, often a critical 
problem for encapsulated biopharmaceuticals [17].  
Our strategy was to develop a delivery platform by a nanocomplex encapsulation technique. This 
method is based on the preparation of a nanocomplex from the specific binding of morphogens to 
heparin [18], followed by coating this nanocomplex with a cationic polyoxyethylene oxide derivative 
(Tetronic-coated nanocomplex). The resulting Tetronic-coated nanocomplex is compatible with 
biodegradable controlled release polymers [19, 20], and could be easily entrapped in poly(lactide-
co-glycolide) (PLGA) microspheres. In this manuscript we report the design of this delivery 
platform, the physicochemical, and pharmaceutical characteristics of the resulting microspheres. 
"
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2. MATERIALS AND METHODS 
2.1 Materials 
For cell studies, we used an immortalized human glioblastoma cell line U-87MG (ATCC 
HTB-14TM), with an intact BMPs signaling pathway and expressing low levels of BMP-7 [12]. 
Dulbecco's Modified Eagle's Medium (DMEM), Dulbecco's Modified Eagle's Medium (DMEM)/
Nutrient F-12 Ham (DMEM/F12 1:1), B-27 serum-free supplement, L-glutamine, penicillin-
streptomycin, trypsin and fetal bovine serum were purchased from Invitrogen (Spain). AccumaxTM 
was obtained from Millipore (Spain). Propidium iodide was purchased from Calbiochem (Spain). 
BD Cytofix™ Fixation Buffer, BD Phosflow™ Perm Buffer III, anti-human Ig PerCP-CyTM5.5-
labeled anti-nestin, Ig phycoerythrin (PE)-labeled anti-doublecortin and Ig PE-labeled anti-glial 
fibrillary acidic protein (GFAP) were purchased from BD Biosciences (Spain). Poly(D,L-lactide-co-
glycolide) 50:50 Resomer® RG 503 (PLGA) (MW=34 kDa) was purchased from Boehringer 
Ingelheim (Germany). Tetronic® 1107 (T1107, HBL=24 MW=15 kDa), α-chymotrypsinogen A from 
bovine pancreas (pI 9.5 MW=25.7 kDa), heparin sodium salt grade IA from porcine intestinal 
mucosae, cotton seed oil, soybean lecithin, bromodeoxyuridine (BrdU), fluorescein isothiocyanate 
(FITC)-conjugated anti-BrdU antibody, Ribonuclease A (RNAse) from bovine pancreas, Triton 
X-100, avidin-peroxidase conjugate and 2,2’-azino-bis(3-ethylbenzothiazoline-6-sulfonic acid) 
(ABTS) were obtained from Sigma Aldrich (Spain). Recombinant human epidermal growth factor 
(EGF), recombinant human fibroblastic growth factor-basic (bFGF), recombinant human bone 
morphogenetic protein 7 (BMP-7) (pI 8.1 MW=28.8 kDa), polyclonal antibody rabbit anti-human 
BMP-7 and polyclonal antibody biotinylated rabbit anti-human BMP-7 were purchased from 
PeproTech (UK). All other solvents and chemicals used were of high-grade purity. 
"
2.2. Microsphere preparation  
The procedure for preparation of the microspheres was based on previous methods described by 
our group [21, 22], but conveniently modified for the efficient encapsulation of heparin-binding 
proteins (nanocomplex encapsulation technique). For optimization of the methodology, we first 
encapsulated α-chymotrypsinogen as a model protein. Briefly, 20 µg or 40 µg of α-
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chymotrypsinogen (for theoretical loadings of 0.1 and 0.2% w/w, respectively) and heparin (1:1 
mass ratio with the protein) were dissolved in 300 µL of sterile water and allowed to interact for 30 
minutes at room temperature (RT). Then, 2.5 mg of Tetronic T1107 were added to this solution and 
the mixture was allowed to interact for other 30 minutes to form Tetronic-coated nanocomplexes. 
These Tetronic-coated nanocomplexes were directly freezed-dried without adding any 
cryoprotectant to consolidate molecular interactions (primary drying at -35oC, secondary drying at 
25oC; VirTis Liophylizer, Genesis 25ES, USA). The freeze-dried cake was resuspended in 400 µL 
of acetonitrile containing 20 mg of PLGA for a final PLGA:T1107 8:1 mass ratio. The organic phase 
was then added dropwise to 4 mL of cotton seed oil containing 0.5% (w/v) soybean lecithin. After 
that, the resulting suspension was sonicated for 20 seconds (output 40W, Branson Sonifier 250, 
Danbury, CT, USA) and stirred for 45 min in an extraction hood. Two milliliters of petroleum ether 
were added to the suspension to harden immature microspheres, and the preparation was agitated 
for another 10 minutes in the extraction hood. Finally, microspheres were collected by filtration 
under vacuum using a nitrocellulose membrane (25 mm, 0.22 µm). Collected microspheres were 
washed with petroleum ether, freeze-dried and stored at 4oC until use. 
The same procedure was used to encapsulate BMP-7. In this case, 2 µg of BMP-7 (theoretical 
loading of 0.01% w/w) and 2 µg of heparin (i.e. 1:1 mass ratio) were dissolved in 300 µL of sterile 
water. Then, these nanocomplexes were processed as described before. 
"
2.3. Morphology and size characterization of the microspheres 
Particle size and morphology of the microspheres were analyzed by scanning electron microscopy 
(SEM) (LEO-435vp, UK). Samples were stuck on metal stubs and coated with gold-palladium 
under vacuum. The size of the microspheres was calculated from micrographs using the computer 
program Digital MicrographTM 3.7.0 (Gatan Software, USA). 
"
2.4. Determination of the encapsulation efficiency for α-chymotrypsinogen 
The encapsulation efficiency of α-chymotrypsinogen was evaluated following a modification of a 
previously described protein extraction method [23]. Briefly, 5 mg of microspheres were dissolved 
in 100 µL of dimethyl sulfoxide under continuous agitation (350 rpm, Heidolf, Promax 2020, 
Germany) during 1 hour. Then, 400 µL of 0.05M NaOH solution containing 0.5% (w/v) SDS were 
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added to the microspheres dissolution and the mixture was incubated for another hour under the 
same conditions. The resulting sample was centrifuged at 7000 RCF during 5 minutes at 25oC. 
The extracted α-chymotrypsinogen was quantified in the supernatant by a standardized 
bicinchoninic acid assay (Micro BCA protein Assay Kit Pierce Biotechnology Inc., USA). 
"
2.5. Determination of the encapsulation efficiency for BMP-7  
The amount of BMP-7 encapsulated in the microspheres was directly quantified by a protein 
extraction method. Briefly, 1 mg of the microspheres was dissolved with 1 mL of dichloromethane 
under continuous agitation (350 rpm, Heidolf, Promax 2020, Germany) for 1 hour. The solution 
was filtered under vacuum using a nitrocellulose membrane (25 mm, 0.22 µm). Then, the 
nitrocellulose membrane was incubated in 3 mL of PBS (pH 7.4) containing 0.1% (w/v) BSA and 
0.05% Tween 20. The membrane was incubated for 6 hours under mild agitation (Heidolph, 
Promax 2020, Germany) at 250 rpm. The extracted BMP-7 was quantified by an enzyme-linked 
immunosorbent assay (ELISA) as described below (section 2.7.). 
"
2.6. In vitro release studies 
Samples comprising 1 mg of PLGA:T1107 (8:1 mass ratio) loaded with BMP-7 and heparin (and 
controls without BMP-7) were incubated with 500 µL of (i) PBS (pH 7.4) containing 1% (w/v) BSA 
or (ii) mitogen-free neurospheres (NSs) culture medium, under agitation (100 rpm) and at 37oC. At 
several scheduled time points, from 12 hours to 90 days, microspheres were centrifuged at 7000 
RCF for 10 min at 4oC, and supernatants collected. Antigenically active BMP-7, released from the 
microspheres to the supernatants, was quantified by ELISA as described in the next section. 
"
2.7. BMP-7 quantification by ELISA 
A 96-well microtiter plate was coated with 100 µL of polyclonal antibody rabbit anti-human BMP-7 
(1 µg/mL in Dulbecco’s PBS, overnight incubation at 4oC in a humid container). The plate was 
washed three times with PBS containing 0.05% Tween 20 (PBST). To minimize unspecific 
interactions, 300 µL of PBS containing 1% (w/v) BSA were added to each well and the plate was 
incubated for 1 hour at 37oC in a humid container. After this time, the plate was washed three 
times with PBST and 100 µL of BMP-7 standard solution and test samples were added to the 
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wells. All standards and test samples were always conveniently diluted in PBS containing 0.1% (w/
v) BSA and 0.05% Tween 20 (PBST-BSA). The plate was incubated for 4 hours at 37oC in a humid 
container and washed thoroughly. Afterwards, 100 µL of polyclonal biotinylated rabbit anti-human 
BMP-7 (0.5 µg/mL) in PBST-BSA were added to each well. The plate was incubated for 2 hours at 
37oC in a humid container and washed three times with PBST. Afterwards, 100 µL of avidin-
peroxidase conjugate diluted 1:2000 in PBST-BSA were added to each well and the plate was 
incubated for 1 hour at 37oC in a humid container. The plate was washed three times and 100 µL 
of substrate (ABTS) added to the wells. After color development, the plate was read at 405 nm on 
a microplate reader (Biorad, Microplate reader model 680, Japan). 
"
2.8 U-87MG neurosphere culture 
Immortalized U-87MG cells were grown in DMEM medium supplemented with 1% penicillin-
streptomycin and 10% fetal bovine serum, in a 5% CO2, 95% humidity incubator. Cells were 
passaged 1-2 times a week. U-87MG cells were then cultured as NSs, being seeded in NSs 
formation medium (DMEM/F-12 (1:1), 1% L-glutamine, B-27 serum-free supplement 1X, 1% 
penicillin-streptomycin, 20 ng/mL EGF, 20 ng/mL bFGF). For expansion of the culture, after 6 
days, NSs in suspension were collected by centrifugation, disaggregated with AccumaxTM and 
re-seeded at a density of 40,000 cells/mL in fresh NSs culture medium in a 100 mm culture 
plate. Prior to any experimentation, cells were dedifferentiated under these conditions for 6 
weeks.  
"
2.9. Neurosphere formation assays 
NSs were disaggregated and individual U-87MG cells plated at clonal conditions (500 cells/well, in 
a 96-well culture plate, 200 µL of NSs growing medium). The effect of BMP-7 was tested by adding 
soluble BMP-7 (in PBS containing 1% (w/v) BSA) to the control medium (50 ng/mL final 
concentration per well). Neuropheres were allowed to grow for 6 days, and their number and size 
were determined by imaging with an optical microscope (Olympus 1X7) with a coupled camera 
(Olympus DP50), and using the software Cell A version 2.6 (Olympus Soft Imaging Solutions 
GmbH).  
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Subsequent experiments involved the collection of BMP-7, released from BMP-7-loaded 
microspheres incubated in NSs medium, at days 30 and 90. The final concentration of released 
BMP-7 was adjusted to 50 ng/mL (dilution with fresh culture medium). These samples were then 
tested in the NSs formation assays as described above. To consider the potential effect of other 
components that could be released from the microspheres (due for example to matrix 
degradation), other controls were additionally tested, namely: (i) 50 ng/mL of heparin; (ii) 313 µg/
mL of Tetronic T1107; (iii) a mixture of BMP-7, Tetronic T1107 and heparin at the concentrations 
described before; (iv) release medium from blank microspheres at 30 and 90 days; (v) control 
medium incubated at 37ºC for 30 days. 
"
2.10. Cell cycle/BrdU incorporation studies 
U-87MG were cultured in NSs medium either with or without BMP-7 (50 ng/mL) for 6 days. NSs 
were then pulsed with BrdU (100 µM, 8 hours incubation at 37ºC). After this time, NSs were 
acutely disaggregated in single cell suspension and washed with PBS. For fixation, ice-cold 
ethanol was added to 1 million cells to a final concentration of 75% (v/v). For BrdU antibody 
staining, cells were washed with PBS, incubated first with 2N HCl in PBS (20 minutes at RT), and 
then with 0.1M sodium borate solution in PBS pH 8.5 (2 hours at RT). Finally, cells were washed 
and incubated with 10µL of fluorescein isothiocyanate (FITC)-conjugated anti-BrdU antibody (1:10 
dilution in PBS containing 0.5% (w/v) BSA and 0.5% Tween 20), 1 hour at RT. Cells were also 
stained with propidium iodide (10 µg/mL in PBS, with 500 µg/mL RNAse and 0.1% Triton X-100, 
overnight incubation at 4ºC) to determine total DNA content. Cells were analyzed by Fluorescence 
Activated Cells Sorting (FACS) (Becton Dickinson, model FACScanTM, Spain). 
"
2.11. Immunocytochemistry 
To determine potential differentiation of U-87MG NSs (stem-like cells) upon incubation with BMP-7, 
specific surface cell markers for neural stem cells, neurons and/or astrocytes, were examined by 
FACS. U-87MG cells from disaggregated NSs, exposed or not to BMP-7, were washed with PBS 
and centrifuged (5 min, 850 RCF). The pellet was resuspended with BD Cytofix™ Fixation Buffer 
and incubated for 20 minutes at RT in the dark. Then, cells were permeabilized for 30 minutes with 
ice-cold BD Phosflow™ Perm Buffer III, also in the dark. Cells were washed twice and incubated 
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on ice for 30 minutes in the dark with 100 µL of PBS containing 0.5% (w/v) BSA and 5 µL/test of 
each conjugated antibody for 1 million of cells (anti-human Ig PerCP-CyTM5.5-labeled anti-nestin, 
Ig PE-labeled anti-doublecortin, Ig PE-labeled anti-GFAP). The cells were washed again 
thoroughly with PBS and resuspended in 400 µL of this buffer for flow cytometry analysis (Becton 
Dickinson, FACScanTM, Spain). 
"
2.12. Statistical analysis 
The size data of microspheres and NSs were analyzed by a one-way ANOVA and a multiple 
comparisons test of Tukey as post-hoc (p<0.05). All the data were analyzed using the software 
Statistica 6.0.  
"
"
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3. RESULTS  
"
3.1. Design of polymeric devices for controlled protein delivery 
3.1.1 Microsphere preparation and encapsulation of α-chymotrypsinogen 
Microspheres were prepared by a newly designed procedure optimized for growth factor 
encapsulation we termed the nanocomplex encapsulation technique. In this method, the protein is 
sequentially complexed by two protective excipients, heparin and Tetronic. Afterwards, these 
Tetronic-coated nanocomplexes are freeze-dried and the resulting polymer cake suspended in a 
PLGA organic solution. PLGA microspheres can then be casted from this organic phase through 
standard procedures, in this case by an O/O emulsion-solvent evaporation technique (for details 
see methods and Fig. 1). 
We selected α-chymotrypsinogen as a model protein to optimize microsphere preparation and 
protein encapsulation due to its similar molecular weight and isoelectric point to BMP-7. 
Microspheres prepared by the nanocomplex encapsulation technique displayed smooth surface 
and regular spherical shape (Fig. 2, A-B). The particle size distribution was broad, typical of 
emulsification methods [24], and had mean values between 10 and 30 µm (Table 1). The 
production yield was excellent for all preparations, above 80%. This feature together with the 
reported physicochemical data suggested the suitability of the production method. 
Microspheres prepared by the nanocomplex encapsulation technique showed a remarkable 
capacity to encapsulate the model protein. The encapsulation efficiency of α-chymotrypsinogen in 
the microspheres was, upon consideration of the statistical deviations, close to 100%; this value 
was independent of the theoretical protein loading for the two levels tested, i.e. 0.1 and 0.2%. For 
benchmarking purposes, we also studied the properties of microspheres prepared by a W/O/W 
double emulsion-solvent evaporation technique, the gold standard method for protein 
encapsulation in PLGA particles (see Supplementary Methods). Microspheres prepared by the 
double emulsion method presented similar characteristics than those from the nanocomplex 
encapsulation technique regarding particle size, particle size heterogeneity, morphology and 
production yield (Table S1, Fig. S1). Their encapsulation efficiency, however, was much lower: 
30-40% (Table S1).  
"
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3.1.2 BMP-7-loaded microspheres  
Encouraged by the promising results obtained for α-chymotrypsinogen, we applied the 
microspheres prepared by the nanocomplex encapsulation technique to BMP-7 delivery. The 
characteristics of BMP-7-loaded microspheres were similar to those observed for the α-
chymotrypsinogen formulations (Table 2; Fig. 2, C-D), and BMP-7 encapsulation was also very 
efficient, above 90%. We consider this last result to be particularly remarkable since encapsulation 
data were obtained from direct determinations, based on protein extraction procedures and 
quantified by ELISA. Therefore, some protein might have not been correctly extracted from the 
matrix, or could have been rendered antigenically inactive during the extraction procedure, making 
the value determined a minimum estimate.  
The in vitro release profiles of BMP-7-loaded microspheres were studied both in PBS (pH 7.4) 
containing 1% w/v BSA, and in mitogen-free NSs culture medium at 37ºC (Fig. 3). The release 
kinetics in both media follows a triphasic profile typical of PLGA microspheres:  burst effect, the lag 
phase and the sustained release phase [19, 21]. For these microspheres the burst effect was 
negligible, below 3% of the protein payload. This absence of burst suggests that the amount of 
BMP-7 on the particle surface is minor, and it is a positive feature of the technology since 
uncontrolled burst release is commonly one order of magnitude larger for this kind of formulations 
[19, 22, 24, 25]. The lag phase, attributed to the time necessary for generating channels in the 
PLGA matrix amenable for proteins to percolate lasted for 15 days in PBS-BSA, and was a little 
shorter in mitogen-free NSs culture medium. From this point, the microspheres showed a sustained 
release of BMP-7 until the 60 days time-point.  
We observed that almost 80% of the BMP-7 microsphere payload is released in its antigenically 
active conformation after 90 days in mitogen-free NSs medium (Fig. 3). This result is critical since it 
shows that the selected microsphere preparation with the Tetronic-coated nanocomplexes is 
capable of protecting BMP-7 during the release phase. 
"
3.2 In vitro antitumoral effect in a glioblastoma initiating cell model 
Having observed a sustained release of antigenically active BMP-7 from the microspheres, we 
decided to study whether the released morphogen had also preserved its bioactivity, and to 
evaluate its efficacy as a tumor suppressor in a GICs model. Previous studies by Piccirillo et al. 
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have shown that the glioma cell line U-87MG cultured in standard 2D conditions is insensitive to 
BMPs, a behavior not replicated by primary cultures of GICs [14]. In this work, we restored 
U-87MG cells sensitivity to BMPs by inducing their dedifferentiation by cultivation in the form of 
NSs [26]. We confirmed by FACS analysis that U-87MG cells cultured as NSs present a highly 
undifferentiated phenotype: almost all cells (>90%) were nestin positive (a neural stem cell 
marker), while only about 20% of them were positive for GFAP or doublecortin (astroglial and 
neural differentiation markers, respectively) (Fig. S2). 
For NS formation assays, U-87MG cells were seeded at clonal conditions, a setup where each NS 
grows from one initiating cell. Due to this, the clonogenic index of the culture is a direct 
measurement of the fraction of cells behaving as GICs. We observed that under control conditions 
around one half of the seeded cells would produce a NS; we refer all clonogenic indexes reported 
to this value (i.e. clonogenic index of the control=1).  
In a first study, we confirmed that BMP-7 has a tumor suppressive effect in the NSs formation 
assay, and that a suitable response was achieved for a dose of 50 ng/mL. This concentration was 
hence fixed for the rest of the experiments.  
At a second stage, we aimed to test the potential effect of the different microsphere components 
that could be leached out during the release studies in the NSs formation assay (Fig. 4A). Tetronic 
showed a significant but minimal reduction in the clonogenic index and heparin had no effect on 
this parameter. BMP-7 led to a 30% reduction in the clonogenic index and this value was not 
modified by the presence of heparin and Tetronic (Fig. 4A, “Mixture”).  
We also analyzed how the different components could have an impact on the size of the resulting 
NSs (Fig. 4B). Addition of BMP-7 resulted in a slight increase in the NSs size. Surprisingly, Tetronic 
and particularly heparin induced some reduction in the NSs size. The experimental group having 
BMP-7, Tetronic and heparin (“Mixture”) showed similar NSs size as compared to the control, 
probably due to a neutralization of the effects observed for BMP-7 and heparin/Tetronic. 
At a third stage, we tested the effect of BMP-7 released from the microspheres and the proper 
controls in the NSs formation assay (Fig. 4, C-D). For that, we took samples of BMP-7 released 
from the microspheres in NSs culture medium (henceforth "release medium"), and we adjusted 
morphogen concentration to 50 ng/mL. BMP-7 released from the microspheres at 30 and 90 days 
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induced a dramatic reduction in the clonogenic index (Fig. 4C, 30dR and 90dR, respectively). This 
result was surprising since BMP-7 in solution at 50 ng/mL was less effective (30%). To explain this 
difference, we tested the effect of release medium previously incubated with blank microspheres 
for 30 and 90 days (30dC and 90dC, respectively). The results showed that this release medium 
generates by itself an inhibitory effect on NS formation, probably due to consumption of some 
nutrients from the media during microsphere incubation. This hypothesis is further clarified since 
we observed similar effects from release medium incubated at 37ºC for extended periods of time, 
even in the absence of microspheres (data not shown).  
Despite the background noise arising from the suppressive action of the incubated release medium, 
BMP-7 bioactivity could still be detected in this assay: a physical mixture of release medium 
incubated with blank microspheres for 90 days and BMP-7 (50 ng/mL) led to further reductions in 
NS formation (Fig. 4C, 90dC+BMP7) as compared to the same conditions without BMP-7. 
According to the statistical analysis, BMP-7 released from the microspheres resulted in a further 
significant decrease in the clonogenic index as compared to this physical mixture of BMP-7 and 90-
days control release medium (p<0.05).  
BMP-7 released from the microspheres also drastically reduced NSs size (90dR, Fig. 4D). We 
explain this reduction by the simultaneous effect of the other released components (i.e. Tetronic and 
heparin, see Fig. 4B), and also by the effect of the consumption of the cell culture medium during 
incubation, as discussed above. Both of these factors were quantified by measuring NSs size for 
release medium incubated with blank microspheres for 90 days (90dC, Fig. 4D). Again, it is 
interesting to note that BMP-7 released from the microspheres was slightly more effective reducing 
NSs size as compared to a physical mixture of BMP-7 and microsphere-incubated release medium 
(90dC+BMP7, Fig. 4D). 
The effect of BMP-7 in the NSs culture is illustrated through microscopy images in Fig. 5. BMP-7 in 
solution does not generate smaller NSs, but rather a lower number of them as compared to the 
control. Release medium incubated with blank microspheres, on the other hand, did have an effect 
in NSs size as mentioned above. Addition of BMP-7 to release medium incubated with blank 
microspheres had a combined effect as NSs were small and there was a higher fraction of cells that 
never initiated NSs formation (arrows). BMP-7 released from the microspheres had the largest 
effect of all, both on NSs size and NSs suppression. 
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3.3 Mechanistic studies on BMP-7 effect 
Based on the biological effects observed, we performed some preliminary experiments to define 
the mechanism of action of BMP-7 in the U-87MG NS model. A limitation of this model is that 
BMP-7 actions seem to be mainly restricted to the tumor initiation stage, whereas only after NSs 
had growth we were able to collect enough cells to run proliferation and phenotyping assays. 
Therefore, we take these results with caution and we advise to consider them within the context of 
other studies performed with primary cultures. 
We first studied BMP-7 effect on cell cycle and proliferation by using a BrdU incorporation assay. 
We noted that BMP-7 supplementation does not result in changes in the cell cycle profile, nor in 
BrdU incorporation (Fig. 6). This suggests that BMP-7 does not exert long-lasting effects on 
proliferation, a conclusion that is supported by our previous observation regarding NSs size upon 
culture with BMP-7 (Fig. 3B).  
An alternative hypothesis to explain why a fraction of the cells never started proliferation even 
though BMP-7 has no long-lasting effect on the cell cycle is that it forces differentiation of the cells 
towards a non-dividing lineage; this implies a permanent loss of their GIC phenotype. Our results 
regarding this hypothesis were not totally conclusive: on one hand, the stem cell marker nestin 
was not reduced for the cell population upon culture with BMP-7. However, we did see some small 
phenotype changes in BMP-7 treated cells, which were less doublecortin positive and more GFAP 
positive (Fig. S2). This effect agrees with previous results from primary culture studies suggesting 
shifting of GICs towards the astroglial lineage. In our experiment, some of the potential pro-
differentiation effect of BMP-7 might be masked by the stated limitations of the model, as well as 
by the dedifferentiation effect of the NSs culture medium used that contains EGF and bFGF.  
"
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4. DISCUSSION 
Dismaying clinical outcomes for glioblastoma treatment seem to be linked to the presence of a 
chemotherapy-resistant cell population with capacity to reinitiate tumor growth: glioblastoma 
initiating cells (GICs) [4, 27]. Academic scientist, and recently pharmaceutical industry, have 
reacted to this paradigm shift by actively seeking drugs capable of targeting cells with tumor 
initiating capacities [28]. BMPs have shown GICs suppressor capacity, an effect that seems to be 
mediated by reprogramming of GICs towards terminally differentiated phenotypes [13, 14, 29].   
We postulate that the therapeutic efficacy of BMPs in vivo will be compromised if they are not 
integrated in a suitable carrier capable of enhancing their biological half-life and deliver them to 
their target region in the brain. This postulate is supported by the fact that clinically-approved 
medicines including BMPs all have in common the use of a delivery platform [30]. Our therapeutic 
proposal is that we can suppress GBM recurrence through the use of a BMP-7-loaded controlled 
release device delivered to the brain by implantation upon primary tumor resection. For that, we 
aimed to encapsulate BMP-7 in microspheres suitable for implantation by minimally-invasive 
surgery and sporting controlled release properties. By providing sustained BMP-7 levels at the 
tumor site, the microspheres would mimic a physiological protective mechanism: in young 
individuals, neural stem cells are recruited to neoplastic foci where they deliver BMP-7 as a 
paracrine tumor suppressive agent [11].   
We selected PLGA as the microspheres’ biodegradable polymer owing to its favorable regulatory 
status for implantation, and to previous positive experiences for the intracraneal delivery of 
cytotoxics [16, 31-33]. Although PLGA devices have been widely investigated for the controlled 
release of biopharmaceuticals [34], labile drugs can be degraded under release conditions when 
encapsulated in these materials due to a known internal acidification process resulting from 
polymer degradation [17, 19]. In the present work, BMP-7 was encapsulated together with heparin 
and Tetronic as protective excipients, a similar technology to that previously reported by our group 
to encapsulate plasmid DNA, fibroblast growth factor, platelet derived growth factor and other 
peptidomimetics [19-22, 25, 35]. Herein, however, we enhanced the interaction of BMP-7 with the 
protective excipients by selecting materials capable of specifically interacting with the drug 
(BMP-7-heparin) or capable of interacting ionically with the BMP-7-heparin nanocomplex 
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(Tetronic). The interaction among the components of the Tetronic-coated nanocomplexes was then 
consolidated by freeze-drying. This method resulted in compositions showing almost complete 
encapsulation of BMP-7, absence of burst release, and sustained protein release for over two 
months in its antigenically active conformation. We believe that this efficient encapsulation of the 
morphogen results from its integration in Tetronic-coated nanocomplexes that should have higher 
interpolymer compatibility vis a vis with the PLGA matrix. 
The efficacy of the microsphere formulation was tested in the U-87MG cell line, cultured as NSs to 
induce GIC-like properties. NS models from immortalized cell lines present limitations compared to 
primary cultures of GICs, most of which have been outlined before in this manuscript. However, 
they also present relevant advantages: (i) they are readily available and do not raise particular 
ethical issues; (ii) they are accessible for any laboratory in unlimited quantities, which is ideal for 
drug screening; and finally, (iii) they should lead to higher comparability of results among different 
laboratories [36]. Our studies have confirmed the tumor suppressive effect of BMP-7 in the 
reported NSs model, and we have discarded the possibility that this effect might be mediated by 
an antiproliferative mechanism. Although we have not been able to confirm this end, it is more 
likely that the tumor suppressive effect is mediated by directed differentiation of GICs towards the 
astroglial lineage as previously reported [11].   
Using the U-87MG NSs model, we have confirmed preserved bioactivity of the BMP-7 released 
from our microspheres, even from samples obtained at the 90 days release point. Interestingly, the 
effect of BMP-7 in NSs model was even greater for the protein released from the microspheres 
than for a physical mixture of soluble BMP-7 and the blank microspheres release medium. With 
these results it is tempting to speculate if heparin, Tetronic and BMP-7 might be released from the 
microspheres in a structured form (i.e. the Tetronic-coated nanocomplex) that could increase their 
tumor suppressive effect. In this sense, heparin is known to modulate the pharmacological effect of 
several binding proteins [37], and several works also report genome-wide effects for Tetronics and 
other polyethylene glycol derivatives [38]. Future studies of our group would try to clarify this point. 
This work is, to the best of our knowledge, one of the pioneers showing a biomaterials-based 
reprogramming strategy for cancer treatment, and to propose biodegradable implantable devices 
for the controlled release of BMPs as a potential GICs suppressive treatment in glioblastoma. We 
have also reported a potential technological platform for this application, showing suitable 
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characteristics for drug encapsulation, controlled release and pharmacological efficacy in a 
relevant cell model. 
"
5. CONCLUSIONS 
Herein we report a controlled release device loaded with a BMP as a potential medicine against 
cancer initiating cells in glioblastoma treatment. To achieve suitable delivery of the BMP in the 
intracranial cavity, we designed a technological platform where BMP-7 was incorporated into 
biodegradable microspheres after enforced interaction with two protective excipients: heparin and 
Tetronic. The delivery systems prepared by this method presented remarkable characteristics: 
almost complete encapsulation, absence of burst release and sustained release of BMP-7 for at 
least two months in a bioactive form. The BMP-7 released from the microspheres was capable of 
suppressing tumor initiation in a glioma initiating cell-like culture model. 
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Tables !
Table 1. Physicochemical and pharmaceutical characteristics of microspheres obtained by the nanocomplex 
encapsulation method loaded with α-chymotrypsinogen (0.1 and 0.2% w/w theoretical loading). The 
composition of the microspheres comprised poly(lactic-co-glycolic acid) (PLGA), Tetronic (TR) and heparin 
(HP). The studied characteristics were: production yield, particle size and encapsulation efficiency (EE). 
Results are means ± SD, n=3. !
* Control with a heparin amount corresponding to the 0.1% loading formulation. 
** Control with a heparin amount corresponding to the 0.2% loading formulation. !!
Table 2. Physicochemical and pharmaceutical characteristics of microspheres obtained by the nanocomplex 
encapsulation method loaded with BMP-7. The composition of the microspheres comprised poly(lactic-co-
glycolic acid) (PLGA), Tetronic (TR) and heparin (HP). The studied characteristics were: production yield, 
particle size and encapsulation efficiency (EE). Results are means ± SD, n=3. !
* Control with a heparin amount corresponding to 0.01% loading. 
Formulation
Theoretical 
loading (%)
Yield (%) Size  (µm) EE (%)
PLGA _ 84.4 ± 8.2 27.9 ± 11.8 -
PLGA:TR _ 79.6 ± 6.6 22.0 ± 9.8 -
PLGA:TR:HP* _ 87.7 ± 6.2 9.0 ± 4.2 -
PLGA:TR:HP    0.1% 83.3 ± 2.9 22.9 ± 10.3 98.5 ± 1.6
PLGA:TR:HP** _ 86.1 ± 3.9 9.7 ± 4.2 -
PLGA:TR:HP    0.2% 87.2 ± 7.7 9.2 ± 2.5 105.5 ± 9.7
Formulation
Theoretical 
loading (%) Yield (%)
Size  (µm) 
Mean ± SD
EE (%)
PLGA:TR/HP* - 87.7 ± 6.2 26.0 ± 12.3 -
PLGA:TR/HP 0.01% 90.5 ± 3.6 21.6 ± 11.1 93.5 ± 4.8
FIGURE CAPTIONS !
Figure 1. Scheme of the concept followed for the preparation of protein-loaded microspheres by the 
nanocomplex encapsulation method.  !
Figure 2. SEM images of microspheres obtained by the nanocomplex encapsulation method. (A) Blank 
microspheres corresponding to 0.2% w/w theoretical loading; (B) microspheres loaded with α-
chymotrypsinogen (0.2% w/w theoretical loading); (C) blank microspheres corresponding to 0.01% w/w 
theoretical loading; (D) microspheres loaded with BMP-7 (0.01% w/w theoretical loading). !
Figure 3. Release of BMP-7 from the microsphere formulation under In vitro conditions. The release 
experiments were performed in two different media: PBS containing 1% (w/v) BSA and mitogens-free 
neurosphere culture medium. Data represents means ±SD, n=3. !
Figure 4. Effect of BMP-7 and the different components of the microspheres on the clonogenic index of 
U-87MG cells cultured as neurospheres (A) and on the size of these neurospheres (B). Effect of BMP-7 
released from the microspheres at 30 and 90 days on the clonogenic index of U-87MG cells cultured as 
neurospheres (C) and on the size of these neurospheres (D). The size of the neurospheres was classified in 
small (area between 1450 and 5918 µm2), medium (area between 5919 and 11340 µm2) and large (area 
between 11341 and 85296 µm2). The groups tested were: neurosphere culture medium (Control), heparin, 
Tetronic, soluble BMP-7 (BMP-7), a mixture of soluble BMP-7, heparin and Tetronic in culture medium 
(Mixture), BMP-7 released from the microspheres at 30 and 90 days (30dR, 90dR), release medium form blank 
microspheres at the same time points (30dC, 90dC), and release medium from blank microspheres mixed with 
soluble BMP-7 (90dC+BMP7). All samples were in neurosphere culture medium and BMP-7 concentration was 
always adjusted to 50 ng/mL. Data represents means ±SD, n=6. !
Figure 5. Optical microscopy images of U-87MG neurospheres upon (A) culture in neurosphere medium for 7 
day (Control) or cultured for the same time in: (B) control medium with soluble BMP-7, (C) control medium 
preincubated at 37ºC in an incubator for 15 days, (D) release medium from blank microspheres (90 days, 
90dC), (E) 90dC supplemented with soluble BMP-7, (F) release medium of BMP-7 loaded microsphere (90 
days time point, 90dR). Arrows show cells that did not initiate neurosphere formation. All samples were in 
neurosphere culture medium, with BMP-7 concentration adjusted to 50 ng/mL. !
Figure 6. Representative cell cycle/BrdU incorporation profiles of U-87MG neurospheres cultured in control 
medium (A) or in control medium with soluble BMP-7 (B). 
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SUPPLEMENTARY MATERIAL   REGUERA-NUÑEZ ET AL. 2013 
!
!
1. SUPPLEMENTARY METHODS 
!
1.1. Microsphere preparation by the double emulsion solvent-evaporation method 
Microspheres were prepared by a water-in-oil-in-water (W/O/W) double emulsion 
solvent evaporation method. Briefly, 20 µg or 40 µg of α-chymotrypsinogen (for 0.1 
and 0.2% w/w theoretical loading, respectively), and heparin (for a final α-
chymotrypsinogen:heparin 1:1 mass ratio) were dissolved in 40 µL of ultrapure water. 
This aqueous solution was added to 400 µL of dichloromethane containing 20 mg of 
PLGA and 2 mg of Tetronic (Tetronic® T90R4, HBL=11, Mw=7.2 KDa, Sigma-Aldrich, 
Spain), and the resulting heterogeneous system was mixed by vortex (UniEquip, 
Model Zx3, Germany) at maximum speed to form a W/O emulsion. This primary 
emulsion was then added to 2 mL of 2% (w/v) polyvinyl alcohol (PVA) solution and 
mixed again by vortex to form a W/O/W double emulsion. This double emulsion was 
diluted with 8 mL of a 0.5% (w/v) PVA solution and magnetically stirred for 3 hours in 
an extraction hood. Afterwards, any remaining solvent was evaporated under reduced 
pressure (Buchi, Rotavapor R-210, Switzerland). The formulation was centrifuged at 
7000 RCF for 10 minutes at 25ºC (Beckman Coulter, Microfuge 22R, Germany). 
Finally, the pellet was frozen and freeze-dried (primary drying: -35ºC, secondary 
drying: 25ºC; VirTis, Genesis 25ES, USA). The obtained microspheres were stored at 
4ºC until used. 
!
2. SUPPLEMENTARY DATA 
!
Table 1. Physicochemical and pharmaceutical characteristics of microspheres obtained 
by the W/O/W double emulsion method loaded with α-chymotrypsinogen (0.1 and 0.2% 
w/w theoretical loadings). The composition of the microspheres comprised poly(lactic-co-
glycolic acid) (PLGA), Tetronic (TR) and heparin (HP). The studied characteristics were: 
production yield, particle size and encapsulation efficiency (EE). Results are means ± SD, 
n=3. 
!
*   Control with a heparin amount corresponding to the 0.1% loading formulation. 
** Control with a heparin amount corresponding to the 0.2% loading formulation. !
Formulation
Theoretical 
loading 
(%)
Yield (%)
Size  (µm) 
EE (%)
PLGA - 51.2±10.9 8.6±7.6 -
PLGA:TR - 85.3±0.9 7.9±4.5 -
PLGA:TR:HP* - 91.0±4.0 19.1±10.9 -
PLGA:TR:HP    0.1 89.6±3.7 10.3±6.3 39.8±0.6
PLGA:TR:HP** - 92.0±2.7 15.8±8.8 -
PLGA:TR:HP    0.2 87.9±3.6 13.4±8.9 36.5±2.3
!
!
 
!
Figure S1. SEM images of microspheres obtained by the W/O/W double-emulsion 
evaporation technique. (A) Blank microspheres control for the 0.2% loading formulation. B) 
Microspheres loaded with α-chymotrypsinogen (0.2% w/w theoretical loading).  
!
A
!
#  
!
Figure S2: Surface markers of U-87MG cells. Cells were cultured as neurospheres in control 
medium or under the same conditions but supplemented with soluble BMP-7. For 
comparison we include negative isotype controls treated and not treated with BMP-7. The 
concentration of BMP-7 was always adjusted to 50 ng/mL. Data shows representative 
results from FACS analysis.
